Moomoo AI 已提取核心信息
On January 11, 2024, Adial Pharmaceuticals, Inc., a Delaware-incorporated company listed on NASDAQ under the trading symbols ADIL and ADILW for its common stock and warrants respectively, held a Special Meeting of Stockholders. During this meeting, stockholders voted on two key proposals. The first proposal, known as the Warrant Exercise Proposal, sought approval for the issuance of up to 3,007,092 shares of common stock upon the exercise of warrants related to a private placement offering that concluded on October 24, 2023. This issuance could potentially exceed 20% of the company's outstanding common stock prior to the offering. The proposal received approval with 432,915 votes in favor, 51,550 against, and 6,621 abstentions. The second proposal, the Adjournment Proposal, was to approve the adjournment of the Special Meeting to...Show More
On January 11, 2024, Adial Pharmaceuticals, Inc., a Delaware-incorporated company listed on NASDAQ under the trading symbols ADIL and ADILW for its common stock and warrants respectively, held a Special Meeting of Stockholders. During this meeting, stockholders voted on two key proposals. The first proposal, known as the Warrant Exercise Proposal, sought approval for the issuance of up to 3,007,092 shares of common stock upon the exercise of warrants related to a private placement offering that concluded on October 24, 2023. This issuance could potentially exceed 20% of the company's outstanding common stock prior to the offering. The proposal received approval with 432,915 votes in favor, 51,550 against, and 6,621 abstentions. The second proposal, the Adjournment Proposal, was to approve the adjournment of the Special Meeting to a later date if necessary. However, this was not required as the Warrant Exercise Proposal passed without the need for further solicitation of votes. The Adjournment Proposal also passed with 436,338 votes in favor, 47,809 against, and 6,939 abstentions. The results of the meeting were filed with the SEC and are detailed in the company's definitive proxy statement.
2024年1月11日，在纳斯达克上市的特拉华州注册公司Adial Pharmicals, Inc. 举行了股东特别会议，其普通股和认股权证的交易代码分别为ADIL和ADILW。在这次会议上，股东对两项关键提案进行了投票。第一项提案，即认股权证行使提案，寻求批准在行使与2023年10月24日结束的私募发行相关的认股权证后，最多发行3,007,092股普通股。此次发行可能会超过公司发行前已发行普通股的20％。该提案以432,915票赞成，51,550票反对，6,621票弃权获得批准。第二项提案，即休会提议，是批准在必要时将特别会议休会。但是，这不是必需的，因为认股权证行使提案无需进一步征集投票即获得通过。休会提案也以436,338票赞成、47,809票反对和6,939票弃权获得通过。会议结果已提交给美国证券交易委员会，并在公司的最终委托书中进行了详细说明。
2024年1月11日，在纳斯达克上市的特拉华州注册公司Adial Pharmicals, Inc. 举行了股东特别会议，其普通股和认股权证的交易代码分别为ADIL和ADILW。在这次会议上，股东对两项关键提案进行了投票。第一项提案，即认股权证行使提案，寻求批准在行使与2023年10月24日结束的私募发行相关的认股权证后，最多发行3,007,092股普通股。此次发行可能会超过公司发行前已发行普通股的20％。该提案以432,915票赞成，51,550票反对，6,621票弃权获得批准。第二项提案，即休会提议，是批准在必要时将特别会议休会。但是，这不是必需的，因为认股权证行使提案无需进一步征集投票即获得通过。休会提案也以436,338票赞成、47,809票反对和6,939票弃权获得通过。会议结果已提交给美国证券交易委员会，并在公司的最终委托书中进行了详细说明。
有用
没用